Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
LLY also announced in mid-February 2024 that a phase 2 trial evaluating tirzepatide for liver disease metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), met its primary endpoint where up to 74% of participants achieved resolution of MASH with no worsening of fibrosis, compared to 13% on placebo
Bradley Quest
The IC 50 of each drug was calculated using GraphPad software
Avoid intravenous (IV) administration unless explicitly directed by a medical professional
E.WhillierS.ChapmanB
US$ 22.38
US$ 29.46
US$ 24.56
US$ 28.97
US$ 21.04
